• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Aptahem

0.46 SEK

-7.06 %

Less than 1K followers

APTA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-7.06 %
-27.52 %
-32.21 %
-58.55 %
-58.55 %
-58.31 %
-97.27 %
-99.58 %
-99.91 %

Aptahem operates in the pharmaceutical industry. The company develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's lead candidate is being developed as an emergency drug intended to prevent the onset of life-threatening organ and tissue damage in patients suffering from sepsis. A large part of the research is carried out in collaboration with partners in the industry. The company was founded in 2014 and is headquartered in Malmö.

Read more
Market cap
11.96M SEK
Turnover
16.14K SEK
Revenue
EBIT %
P/E
Dividend yield-%
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
ShowingAll content types

Financial calendar
27.8.
2026

Interim report Q2'26

Press release22.06.2026 klo 09.19

Aptahem: Newsletter June 2026

Aptahem
Press release17.06.2026 klo 09.30

Aptahem Improves Quality and Manufacturing Efficiency in a New Apta-1 Test Batch

Aptahem
Press release05.06.2026 klo 15.12

Aptahem to Participate at IOPC 2026 in Athens

Aptahem

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release11.05.2026 klo 11.51

Aptahem: Newsletter May 2026

Aptahem
Press release19.12.2025 klo 17.00

Aptahem: Newsletter December 2025

Aptahem
Regulatory press release05.12.2025 klo 09.52

Aptahem receives patent protection in China for patent family 2

Aptahem
Press release30.10.2025 klo 10.56

Aptahem's webinar "Strategic Direction and Planned US Listing" now available

Aptahem
Press release22.10.2025 klo 13.49

Aptahem Announces English-Language Webinar on Strategic Direction and Planned U.S. Listing

Aptahem
Press release21.10.2025 klo 09.45

Aptahem: Newsletter October 2025

Aptahem
Press release25.09.2025 klo 16.19

Aptahem moves forward with focus on U.S. listing strategy, regulatory progress, and partner engagement following outcome of rights issue

Aptahem
Regulatory press release23.09.2025 klo 12.53

Aptahem receives Notice of Allowance in China for patent family 2

Aptahem
Press release19.09.2025 klo 09.44

Aptahem Outlines Ongoing Preparations for Planned U.S. Listing and Announces Webinar Invitation

Aptahem
Regulatory press release27.08.2025 klo 17.53

Aptahem is applying to the FDA's CNPV pilot program for accelerated drug review

Aptahem
Press release27.08.2025 klo 14.33

Aptahem: Newsletter No 2, August 2025

Aptahem
Regulatory press release26.08.2025 klo 10.21

Aptahem announces Strategic Direction for U.S. Listing to Enable Phase 2 Study and build portfolio assets value

Aptahem
Regulatory press release20.08.2025 klo 11.07

Aptahem files provisional patent application in USA for new indications for Apta-1

Aptahem
Regulatory press release13.08.2025 klo 15.13

Aptahem Applies to FDA PreCheck Program - Strategic Step Toward Faster, Higher-Quality Drug Manufacturing

Aptahem
Regulatory press release20.05.2025 klo 17.20

Aptahem receives strong interest in partnership from a European pharmaceutical company

Aptahem